I suggested to look at inconsistency inside therapy effects having necessary I2 analytics (in the event the I2 try > 50%)
We structured pooled analyses despite statistically significant heterogeneity. Instead, i proposed investigating heterogeneity with a good priori outlined patient qualities, e. Because post hoc analyses regarding statistical power isn’t necessary[47-50], we downgraded the quality of[...]
